Search

Your search keyword '"Miglietta, Loredana"' showing total 33 results
Start Over Author "Miglietta, Loredana" Publication Year Range Last 50 years
33 results on '"Miglietta, Loredana"'

1. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial

Author

Conte, Benedetta, Bruzzone, Marco, Lambertini, Matteo, Poggio, Francesca, Bighin, Claudia, Blondeaux, Eva, De Laurentiis, Michelino, Valle, Enrichetta, Cognetti, Francesco, Nisticò, Cecilia, De Placido, Sabino, Garrone, Ornella, Gamucci, Teresa, Montemurro, Filippo, Puglisi, Fabio, Cardinali, Barbara, Fregatti, Piero, Miglietta, Loredana, Boccardo, Francesco, Ceppi, Marcello, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

2. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Author

Conte, Benedetta, Fabi, Alessandra, Poggio, Francesca, Blondeaux, Eva, Dellepiane, Chiara, D’Alonzo, Alessia, Buono, Giuseppe, Arpino, Grazia, Magri, Valentina, Naso, Giuseppe, Presti, Daniele, Mura, Silvia, Fontana, Andrea, Cognetti, Francesco, Molinelli, Chiara, Pastorino, Simona, Bighin, Claudia, Miglietta, Loredana, Boccardo, Francesco, Lambertini, Matteo, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

3. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study

Author

Lambertini, Matteo, Fontana, Valeria, Massarotti, Claudia, Poggio, Francesca, Dellepiane, Chiara, Iacono, Giuseppina, Abate, Annalisa, Miglietta, Loredana, Ferreccio, Chiara, Pescio, Maria Carolina, Conte, Benedetta, Blondeaux, Eva, Bighin, Claudia, D'Alonzo, Alessia, Vaglica, Marina, Zanardi, Elisa, Boccardo, Francesco, Ballestrero, Alberto, Anserini, Paola, and Del Mastro, Lucia

Published
2018
Full Text
View/download PDF

4. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial

Author

Del Mastro, Lucia, Levaggi, Alessia, Michelotti, Andrea, Cavazzini, Giovanna, Adami, Francesca, Scotto, Tiziana, Piras, Margherita, Danese, Saverio, Garrone, Ornella, Durando, Antonio, Accortanzo, Valeria, Bighin, Claudia, Miglietta, Loredana, Pastorino, Simona, Pronzato, Paolo, Castiglione, Federico, Landucci, Elisabetta, Conte, PierFranco, and Bruzzi, Paolo

Published
2016
Full Text
View/download PDF

13. T-DM1 EFFICACY AND ACTIVITY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PROGRESSING AFTER FRONTLINE TAXANE PLUS PERTUZUMAB AND TRASTUZUMAB: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY OF THE GRUPPO ITALIANO MAMMELLA (GIM) STUDY GROUP

Author

Conte, Benedetta, primary, Fabi, Alessandra, additional, Poggio, Francesca, additional, Blondeaux, Eva, additional, Dellepiane, Chiara, additional, D’alonzo, Alessia, additional, Buono, Giuseppe, additional, Arpino, Grazia, additional, Magri, Valentina, additional, Naso, Giuseppe, additional, Presti, Daniele, additional, Mura, Silvia, additional, Fontana, Andrea, additional, Cognetti, Francesco, additional, Molinelli, Chiara, additional, Pastorino, Simona, additional, Bighin, Claudia, additional, Miglietta, Loredana, additional, Boccardo, Francesco, additional, Lambertini, Matteo, additional, and Del Mastro, Lucia, additional

Published
2019
Full Text
View/download PDF

15. The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients

Author

Lambertini, Matteo, primary, Anserini, Paola, additional, Fontana, Valeria, additional, Poggio, Francesca, additional, Iacono, Giuseppina, additional, Abate, Annalisa, additional, Levaggi, Alessia, additional, Miglietta, Loredana, additional, Bighin, Claudia, additional, Giraudi, Sara, additional, D’Alonzo, Alessia, additional, Blondeaux, Eva, additional, Buffi, Davide, additional, Campone, Francesco, additional, Merlo, Domenico F., additional, and Del Mastro, Lucia, additional

Published
2017
Full Text
View/download PDF

16. Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases.

Author

Buonomo, Barbara, Brunello, Antonella, Noli, Stefania, Miglietta, Loredana, Del Mastro, Lucia, Lambertini, Matteo, and Peccatori, Fedro Alessandro

Subjects
BREAST tumors, COMBINED modality therapy, CONTRACEPTION, COUNSELING, HEALTH care teams, TAMOXIFEN, SYSTEMATIC reviews, PERIMENOPAUSE, MATERNAL exposure, PREGNANCY
Abstract

Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. According to guidelines, the use of nonhormonal barrier contraception is recommended during tamoxifen treatment and up to 3 months after its interruption prior to attempting conception. Nevertheless, when conception occurs inadvertently during tamoxifen treatment, the effects on the fetus and on the course of pregnancy are still not completely known. Here, we report 3 cases of young women who accidentally became pregnant while taking tamoxifen and perform a systematic review of the literature to provide more elements for better and clear multidisciplinary counselling of women facing this challenging situation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients

Author

Lambertini, Matteo, Giraudi, Sara, D'Alonzo, Alessia, Blondeaux, Eva, Buffi, Davide, Campone, Francesco, Merlo, Domenico Franco, Del Mastro, Lucia, Anserini, Paola, Fontana, Valeria, Poggio, Francesca, Iacono, Giuseppina, Abate, Annalisa, Levaggi, Alessia, Miglietta, Loredana, Bighin, Claudia, Lambertini, Matteo, Giraudi, Sara, D'Alonzo, Alessia, Blondeaux, Eva, Buffi, Davide, Campone, Francesco, Merlo, Domenico Franco, Del Mastro, Lucia, Anserini, Paola, Fontana, Valeria, Poggio, Francesca, Iacono, Giuseppina, Abate, Annalisa, Levaggi, Alessia, Miglietta, Loredana, and Bighin, Claudia

Abstract

Background: Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. Methods: The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues. It is composed of two distinctive studies: PREFER-FERTILITY and PREFER-PREGNANCY. The PREFER-FERTILITY study is enrolling premenopausal patients aged 18-45 years, diagnosed with non-metastatic breast cancer, who are candidates to (neo)adjuvant chemotherapy and not previously exposed to anticancer therapies. The primary objective is to obtain and centralize data about patients' preferences and choices towards the available fertility preserving procedures. The success and safety of these strategies and the hormonal changes during chemotherapy and study follow-up are secondary objectives. The PREFER-PREGNANCY study is enrolling survivors achieving a pregnancy after prior history of breast cancer and patients diagnosed with pregnancy-associated breast cancer (PABC). The primary objectives are to obtain and centralize data about the management and clinical outcomes of these women. Patients' survival outcomes, and the fetal, obstetrical and paediatric care of their children are secondary objectives. For both studies, the initial planned recruitment period is 5 years and patients will remain in active follow-up for up to 15 years. The PREFER-FERTILITY study was first activated in November 2012, and the PREFER-PREGNANCY study i, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

18. OR65 - T-DM1 EFFICACY AND ACTIVITY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PROGRESSING AFTER FRONTLINE TAXANE PLUS PERTUZUMAB AND TRASTUZUMAB: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY OF THE GRUPPO ITALIANO MAMMELLA (GIM) STUDY GROUP

Author

Conte, Benedetta, Fabi, Alessandra, Poggio, Francesca, Blondeaux, Eva, Dellepiane, Chiara, D’alonzo, Alessia, Buono, Giuseppe, Arpino, Grazia, Magri, Valentina, Naso, Giuseppe, Presti, Daniele, Mura, Silvia, Fontana, Andrea, Cognetti, Francesco, Molinelli, Chiara, Pastorino, Simona, Bighin, Claudia, Miglietta, Loredana, Boccardo, Francesco, Lambertini, Matteo, and Del Mastro, Lucia

Published
2019
Full Text
View/download PDF

19. Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study

Author

Bighin, Claudia, primary, Dozin, Beatrice, additional, Poggio, Francesca, additional, Ceppi, Marcello, additional, Bruzzi, Paolo, additional, D’Alonzo, Alessia, additional, Levaggi, Alessia, additional, Giraudi, Sara, additional, Lambertini, Matteo, additional, Miglietta, Loredana, additional, Vaglica, Marina, additional, Fontana, Vincenzo, additional, Iacono, Giuseppina, additional, Pronzato, Paolo, additional, and Mastro, Lucia Del, additional

Published
2017
Full Text
View/download PDF

20. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial

Author

Del Mastro, Lucia, primary, Levaggi, Alessia, additional, Michelotti, Andrea, additional, Cavazzini, Giovanna, additional, Adami, Francesca, additional, Scotto, Tiziana, additional, Piras, Margherita, additional, Danese, Saverio, additional, Garrone, Ornella, additional, Durando, Antonio, additional, Accortanzo, Valeria, additional, Bighin, Claudia, additional, Miglietta, Loredana, additional, Pastorino, Simona, additional, Pronzato, Paolo, additional, Castiglione, Federico, additional, Landucci, Elisabetta, additional, Conte, PierFranco, additional, and Bruzzi, Paolo, additional

Published
2015
Full Text
View/download PDF

21. PO54 ACTIVITY AND DURATION OF CHEMOTHERAPY IN DIFFERENT BIOLOGIC SUBTYPES (BS) IN METASTATIC BREAST CANCER (MBC) PATIENTS

Author

Lambertini, Matteo, primary, Bighin, Claudia, additional, Del Mastro, Lucia, additional, Dozin, Beatrice, additional, Levaggi, Alessia, additional, Giraudi, Sara, additional, D'Alonzo, Alessia, additional, Poggio, Francesca, additional, Iacono, Giuseppina, additional, Vecchio, Stefania, additional, Miglietta, Loredana, additional, and Pronzato, Paolo, additional

Published
2013
Full Text
View/download PDF

22. Activity and duration of chemotherapy (CT) in different biologic subtype (BS) in metastatic breast cancer (MBC) patients (P).

Author

Bighin, Claudia, primary, Del Mastro, Lucia, additional, Dozin, Beatrice, additional, Giraudi, Sara, additional, Levaggi, Alessia, additional, D'Alonzo, Alessia, additional, Lambertini, Matteo, additional, Poggio, Francesca, additional, Iacono, Giuseppina, additional, Miglietta, Loredana, additional, and Pronzato, Paolo, additional

Published
2013
Full Text
View/download PDF

23. Prospective observational study on fertility preservation in young early breast cancer patients: The PREFER (Pregnancy and Fertility) trial.

Author

Lambertini, Matteo, primary, Anserini, Paola, additional, Fontana, Valeria, additional, Abate, Annalisa, additional, Sozzi, Fausta, additional, Merlo, Franco, additional, Pronzato, Paolo, additional, Bighin, Claudia, additional, Levaggi, Alessia, additional, D'Alonzo, Alessia, additional, Giraudi, Sara, additional, Iacono, Giuseppina, additional, Miglietta, Loredana, additional, Poggio, Francesca, additional, and Del Mastro, Lucia, additional

Published
2013
Full Text
View/download PDF

25. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.

Author

Mastro, Lucia, Levaggi, Alessia, Michelotti, Andrea, Cavazzini, Giovanna, Adami, Francesca, Scotto, Tiziana, Piras, Margherita, Danese, Saverio, Garrone, Ornella, Durando, Antonio, Accortanzo, Valeria, Bighin, Claudia, Miglietta, Loredana, Pastorino, Simona, Pronzato, Paolo, Castiglione, Federico, Landucci, Elisabetta, Conte, PierFranco, and Bruzzi, Paolo

Abstract

The study was designed to compare an anthracycline-containing regimen to a regimen combining both anthracycline and paclitaxel as adjuvant therapy for high-risk breast cancer patients. In this multicenter, randomized phase-III trial, node-positive early breast cancer patients were randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m, epirubicin 60 mg/m and cyclophosphamide 600 mg/m, day 1, every 3 weeks) or 4 cycles of EP (epirubicin 90 mg/m and paclitaxel 175 mg/m, day 1, every 3 weeks). The primary endpoint was overall survival (OS). Secondary endpoints included toxicity and event-free survival (EFS). From 1996 to 2001, 1055 patients were enrolled. At a median follow-up of 12.8 years, 335 deaths had been recorded. The 10-year OS was 73 % (95 % CI 69-77) in the FEC arm and 74 % (95 % CI 70-78) in the EP arm ( p = 0.405). The 10-year EFS was 51 % (95 % CI 45-56) in the FEC arm and 49 % (95 % CI 44-55) in the EP arm ( p = 0.572). No difference in the hazard of death was observed (HR for EP 0.85, 95 % CI 0.68-1.06, p = 0.15). Patients treated with FEC experienced more frequently nausea and vomiting, stomatitis, and leukopenia as compared to patients treated with EP. Toxicities which occurred more frequently with EP were anemia, fever, myalgias, and neurotoxicity. Our study failed to demonstrate a superiority of an adjuvant treatment with four EP as compared to six FEC in node-positive breast cancer patients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

32. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Author

Andrea Fontana, Lucia Del Mastro, Matteo Lambertini, S. Pastorino, Chiara Molinelli, Giuseppe Naso, Francesca Poggio, Valentina Magri, Claudia Bighin, Giuseppe Buono, Grazia Arpino, Loredana Miglietta, Alessandra Fabi, Daniele Presti, Francesco Boccardo, Alessia D'Alonzo, Chiara Dellepiane, Francesco Cognetti, Silvia Mura, Eva Blondeaux, Benedetta Conte, Conte, Benedetta, Fabi, Alessandra, Poggio, Francesca, Blondeaux, Eva, Dellepiane, Chiara, D'Alonzo, Alessia, Buono, Giuseppe, Arpino, Grazia, Magri, Valentina, Naso, Giuseppe, Presti, Daniele, Mura, Silvia, Fontana, Andrea, Cognetti, Francesco, Molinelli, Chiara, Pastorino, Simona, Bighin, Claudia, Miglietta, Loredana, Boccardo, Francesco, Lambertini, Matteo, and Del Mastro, Lucia

Subjects
0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, Ado-Trastuzumab Emtansine, chemistry.chemical_compound, 0302 clinical medicine, Trastuzumab, Retrospective Studie, Antineoplastic Combined Chemotherapy Protocols, Breast, Prospective Studies, Treatment Failure, Prospective cohort study, Mastectomy, Middle Aged, Metastatic breast cancer, Neoadjuvant Therapy, Progression-Free Survival, Italy, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Real world evidence, Advanced breast cancer, Prospective study, Trastuzumab emtansine, Female, Pertuzumab, Breast Neoplasm, medicine.drug, Human, Adult, medicine.medical_specialty, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Follow-Up Studie, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Humans, Aged, Retrospective Studies, Taxane, Antineoplastic Combined Chemotherapy Protocol, business.industry, medicine.disease, Confidence interval, Prospective Studie, 030104 developmental biology, chemistry, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy. Patients and Methods Eligible patients were identified within the Gruppo Italiano Mammella (GIM) 14/BIOMETA study, a retrospective/prospective multicenter study on treatment patterns and outcomes of patients with metastatic breast cancer ( ClinicalTrials.gov Identifier: NCT02284581 ). We searched for patients who received second-line T-DM1 after taxane plus trastuzumab and pertuzumab between November 15, 2013 and May 31, 2018. We calculated median PFS, median time to treatment failure (TTF), prolonged duration of therapy (PDT), objective response rate (ORR), and 1-year OS. Results Of 445 patients with HER2+ metastatic breast cancer, 77 were eligible for the analysis. At a median follow-up of 7 months, median PFS was 6.3 months (95% confidence intervals [CI], 4.8-7.7 months), and median TTF was 6.2 months (95% CI, 4-8.6 months). More than one-third of patients (37.6%; n = 29) experienced PDT with an ORR of 27.1%. At data cutoff, the median OS was not reached, and the 1-year OS was 82%. Conclusions Our results show meaningful activity of T-DM1 after front-line pertuzumab plus trastuzumab and a taxane, with about 27% of patients having an objective response and 40% of patients achieving durable disease control.

Published
2019

33. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.

Author

Miglietta L, Vanella P, Canobbio L, Parodi MA, Guglielmini P, and Boccardo F

Subjects
Breast Neoplasms metabolism, Breast Neoplasms pathology, Female, Humans, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Cell Proliferation, Ki-67 Antigen metabolism, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
Abstract

Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC)., Patients and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression., Results: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate., Conclusion: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results